Communicable Episode 04: The BLING III trial & continuous β-lactam infusion - should these results change your practice?

Kathryn Hostettler(European Society of Clinical Microbiology and Infectious Diseases), Angela Huttner(University Hospital of Geneva), David L. Paterson(The University of Queensland), Joshua S. Davis(John Hunter Hospital), Erin K McCreary(University of Pittsburgh Medical Center)
CMI Communications
November 7, 2024
10.1016/j.cmicom.2024.105046
Cited by 1

Related Papers

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
|Clinical Microbiology Reviews|2015|5.1k
Antimicrobial Resistance in ESKAPE Pathogens
|Clinical Microbiology Reviews|2020|2k
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance
|JAMA|2018|779
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
|The Lancet Infectious Diseases|2017|521
Analysis of Antibiotic Resistance Genes in Multidrug-Resistant <i>Acinetobacter</i> sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center
|Antimicrobial Agents and Chemotherapy|2006|481